A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56. RESULTS: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment. CONCLUSIONS: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In adolescents with obesity, liraglutide 3.0 mg reduced BMI by 4.3% over 56 weeks compared to 0.3% with placebo, with early treatment response predicting long-term effectiveness.39”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [39]
In the citing paper
“but modest reduction in main CVD factors over 56 weeks of treatment.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“In a key RCT, there were notable reductions in BMI SDS and higher percentages of participants achieving ≥ 5% and ≥ 10% Weight loss compared to placebo and the BMI standard-deviation score at week 56 (estimated difference, − 0.22; 95% confidence interval [CI], − 0.37 to − 0.08; P = 0.002) [112]”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“Approved by FDA/EMA from age 6.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“The liraglutidetreated group demonstrated a placebo-subtracted weight reduction of 5% (29).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [29]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Establishing a standard definition for child overweight and obesity worldwide: international survey
Cole, T. J. (2000) · BMJ · doi:10.1136/bmj.320.7244.1240 · Cited by 16,480
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Freedman, D. S., Mei, Z., Srinivasan, S. R., Berenson, G. S., & Dietz, W. H. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.08.042 · Cited by 1,562
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Research works printed but not linked: 1
- Frelut M-L De Filippo G. Drug treatment of child and adolescent obesity. In: Frelut M-L ed. ECOG eBook on child and adolescent obesity. 2015 (https://ebook.ecog-obesity.eu/chapter-treatment/drug-treatment-of-child-and-adolescent-obesity/).
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Hampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Obesity in children and adolescents: epidemiology, causes, assessment, and management
Jebeile, H., Kelly, A. S., O'Malley, G., & Baur, L. A. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00047-x · Cited by 1,099
Self-citationCusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Once-weekly semaglutide in adolescents with obesity
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208601 · Cited by 730
Self-citationChildhood and Adolescent Obesity: A Review
Kansra, A. R., Lakkunarajah, S., & Jay, M. S. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2020.581461 · Cited by 514
“0mg)/day plus lifestyle therapy group compared to placebo plus lifestyle therapy in children between the ages of 12–18 years (171).”
MethodSyn, N. L., Cummings, D. E., Wang, L. Z., Lin, D. J., Zhao, J. J., Loh, M., Koh, Z. J., Chew, C. A., Loo, Y. E., Tai, B. C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00591-2 · Cited by 521
Lister, N. B., Baur, L. A., Felix, J. F., Hill, A. J., Marcus, C., Reinehr, T., Summerbell, C., & Wabitsch, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00435-4 · Cited by 500
Self-citationGLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
“Liraglutide has also been approved in several countries for the treatment of adolescents with obesity based on the results of a 56-weeklong randomized controlled trial in male and female adolescents, 12e <18 years of age [80].”
BackgroundKerr, J. A., Patton, G. C., Cini, K. I., Abate, Y. H., Abbas, N., Abd Al Magied, A. H. A., Abd ElHafeez, S., Abd-Elsalam, S., Abdollahi, A., Abdoun, M., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00397-6 · Cited by 460
“81,105 This field is moving quickly, and evidence for the efficacy of these treatments is growing in young people 106–110 and children.”
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
14. Children and Adolescents: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s014 · Cited by 367
Mapping the effectiveness and risks of GLP-1 receptor agonists
Xie, Y., Choi, T., & Al-Aly, Z. (2025) · Nature Medicine · doi:10.1038/s41591-024-03412-w · Cited by 300
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Pediatric obesity—Long‐term consequences and effect of weight loss
Marcus, C., Danielsson, P., & Hagman, E. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13547 · Cited by 267
Self-citationMechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Medications for Obesity: A Review
Gudzune, K. A., & Kushner, R. F. (2024) · JAMA · doi:10.1001/jama.2024.10816 · Cited by 263
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
“These studies demonstrate that administering the GLP-1 receptor antagonist exendin (9 – 39) directly into the brain increases food consumption in satiated rats.”
Background14. Children and Adolescents: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s014 · Cited by 200
Obesity in South and Southeast Asia—A new consensus on care and management
Tham, K. W., Abdul Ghani, R., Cua, S. C., Deerochanawong, C., Fojas, M., Hocking, S., Lee, J., Nam, T. Q., Pathan, F., Saboo, B., et al. (2023) · Obesity Reviews · doi:10.1111/obr.13520 · Cited by 187
“GI adverse events and adverse events leading to discontinuation were more common in the liraglutide group than in the placebo group.(189)”
BackgroundThe Related Metabolic Diseases and Treatments of Obesity
Yang, M., Liu, S., & Zhang, C. (2022) · Healthcare · doi:10.3390/healthcare10091616 · Cited by 170
14. Children and Adolescents: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s014 · Cited by 173
14. Children and Adolescents: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s014 · Cited by 165
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff, A. M., & Kushner, R. F. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-014919 · Cited by 158
Killion, E. A., Chen, M., Falsey, J. R., Sivits, G., Hager, T., Atangan, L., Helmering, J., Lee, J., Li, H., Wu, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18751-8 · Cited by 151
Phentermine/Topiramate for the Treatment of Adolescent Obesity
Kelly, A. S., Bensignor, M. O., Hsia, D. S., Shoemaker, A. H., Shih, W., Peterson, C., & Varghese, S. T. (2022) · NEJM Evidence · doi:10.1056/evidoa2200014 · Cited by 169
“7,8 Regarding notable secondary outcomes in the current trial, weight loss with PHEN/TPM at both the mid and top doses reduced waist circumference compared with placebo.”
BackgroundInfluentialSelf-citationObesity in Adolescents: A Review
Kelly, A. S., Armstrong, S., Michalsky, M. P., & Fox, C. K. (2024) · JAMA · doi:10.1001/jama.2024.11809 · Cited by 184
Self-citationLiraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial
Fox, C. K., Barrientos-Pérez, M., Bomberg, E. M., Dcruz, J., Gies, I., Harder-Lauridsen, N. M., Jalaludin, M. Y., Sahu, K., Weimers, P., Zueger, T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2407379 · Cited by 142
Self-citationGLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119
Ryan, P. M., Seltzer, S., Hayward, N. E., Rodriguez, D. A., Sless, R. T., & Hawkes, C. P. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.05.009 · Cited by 111
Berg, S., Stickle, H., Rose, S. J., & Nemec, E. C. (2025) · Obesity Reviews · doi:10.1111/obr.13929 · Cited by 111
“23 As time passes after the cessation of GLP-1RA treatment, the mean weight and BMI regain also increase, regardless of the GLP-1RA used.”
InfluentialGLP‐1 agonists for obesity and type 2 diabetes in children: Systematic review and meta‐analysis
Chadda, K. R., Cheng, T. S., & Ong, K. K. (2021) · Obesity Reviews · doi:10.1111/obr.13177 · Cited by 103
“63).(24) Hence, our findings are reassuring in showing detectable glycemic benefits of GLP-1 agonists in children with obesity without diabetes, as well as in those with (pre-)diabetes.”
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
“The phase III trials of liraglutide and semaglutide in adolescents (≥12 years of age) with obesity and T2DM have provided valuable evidence for their effectiveness in this group of patients 91,141,142 .”
Thomas-Eapen, N. (2021) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.04.002 · Cited by 120
The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits
Hinney, A., Körner, A., & Fischer-Posovszky, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00716-0 · Cited by 101
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Adolescent PCOS: a postpubertal central obesity syndrome
Ibáñez, L., & de Zegher, F. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.006 · Cited by 97
The adolescent with obesity: what perspectives for treatment?
Nicolucci, A., & Maffeis, C. (2022) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-022-01205-w · Cited by 137
“At week 56, there was no substantial difference between treatment groups in glycemic and cardiometabolic variables or in overall weight-related quality of life [54].”
BackgroundVosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T., Karges, B., Kordonouri, O., et al. (2016) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-111213 · Cited by 91
Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Vilarrasa, N., San Jose, P., Rubio, M. Á., & Lecube, A. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s223618 · Cited by 88
Roth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., & Abuzzahab, M. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14224 · Cited by 87
“Indeed, in a recent publication in adolescents with severe obesity, escalation to a high dose of liraglutide (3 mg per day) over a 56-week intervention showed a 5% BMI reduction in 43% versus 19% in the placebo-treated group.(22) There may be a difference in hypothalamic injury that impacts the response to therapy.”
BackgroundZhou, J., Zheng, Y., Xu, B., Long, S., Zhu, L.-E., Liu, Y., Li, C., Zhang, Y., Liu, M., & Wu, X. (2024) · BMC Medicine · doi:10.1186/s12916-024-03274-6 · Cited by 82
“In the randomized controlled trial (RCT) by Kelly et al. [37], a suicide case in the liraglutide group was reported to have a history of attention deficit hyperactivity disorder, which is a potential factor of SSIBs.”
BackgroundInfluentialCharacterization of the genetic architecture of infant and early childhood body mass index
Helgeland, Ø., Vaudel, M., Solé-Navais, P., Flatley, C. J., Juodakis, J., Bačelis, J., Koløen, I. L., Knudsen, G. P., Johansson, B. B., Magnus, P. M., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00549-1 · Cited by 91
Detka, J., & Głombik, K. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00274-8 · Cited by 79
“Lately, a GLP-1R agonist, liraglutide, has also been approved by the FDA for the treatment of adolescent obesity [14].”
BackgroundChildhood obesity: A review of current and future management options
Apperley, L. J., Blackburn, J., Erlandson‐Parry, K., Gait, L., Laing, P., & Senniappan, S. (2021) · Clinical Endocrinology · doi:10.1111/cen.14625 · Cited by 98
“intestinal adverse effects were noted in the liraglutide group and highlighted that the medication may not suit all individuals.(76) Mastrandrea et al.”
BackgroundResultInfluentialO’Connor, E., Evans, C. V., Henninger, M. L., Redmond, N., & Senger, C. A. (2024) · JAMA · doi:10.1001/jama.2024.6739 · Cited by 95
Liraglutide for Weight Management in Children and Adolescents With Prader–Willi Syndrome and Obesity
Diene, G., Angulo, M., Hale, P. M., Jepsen, C. H., Hofman, P. L., Hokken‐Koelega, A. C. S., Ramesh, C. K., Turan, S., & Tauber, M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac549 · Cited by 86
Self-citationCurrent Treatments for Patients with Genetic Obesity
Faccioli, N., Poitou, C., Clément, K., & Dubern, B. (2023) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2023.2023-3-2 · Cited by 122
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Moll, H., Frey, E., Gerber, P., Geidl, B., Kaufmann, M., Braun, J., Beuschlein, F., Puhan, M. A., & Yebyo, H. G. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102661 · Cited by 73
Clinical guidelines «Obesity in children»
Peterkova, V. A., Bezlepkina, O. B., Bolotova, N. V., Bogova, E. A., Vasyukova, O. V., Girsh, Y. V., Kiyaev, A. V., Kostrova, I. B., Malievskiy, O. A., Михайлова, Е. Г., et al. (2021) · Problems of Endocrinology · doi:10.14341/probl12802 · Cited by 135
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O’Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 71
Järvholm, K., Janson, A., Peltonen, M., Neovius, M., Gronowitz, E., Engström, M., Laurenius, A., Beamish, A. J., Dahlgren, J., Sjögren, L., et al. (2023) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00373-x · Cited by 83
Yu, X., Chen, S., Funcke, J.-B., Straub, L. G., Pirro, V., Emont, M. P., Droz, B. A., Collins, K. A., Joung, C., Pearson, M. J., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.11.003 · Cited by 67
Tzang, C.-C., Wu, P.-H., Luo, C.-A., Chen, Z.-T., Lee, Y.-T., Huang, E. S., Kang, Y.-F., Lin, W.-C., Tzang, B.-S., & Hsu, T.-C. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103680 · Cited by 73
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68
Progress in Pharmacotherapy for Obesity
Yanovski, S. Z., & Yanovski, J. A. (2021) · JAMA · doi:10.1001/jama.2021.9486 · Cited by 67
Dyslipidemia in Pediatric Type 2 Diabetes Mellitus
Sunil, B., & Ashraf, A. P. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01336-6 · Cited by 79
Addressing psychosocial health in the treatment and care of adolescents with obesity
Jebeile, H., Cardel, M. I., Kyle, T. K., & Jastreboff, A. M. (2021) · Obesity · doi:10.1002/oby.23194 · Cited by 83
“0 mg in adolescents with obesity (77), a significant reduction in BMI z score of 0.”
BackgroundThe limits and challenges of antiobesity pharmacotherapy
Gadde, K. M., & Atkins, K. D. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1748599 · Cited by 65
“In a recently reported RCT among 251 adolescents [53], treatment with liraglutide 3.”
BackgroundHunt, J. E., Holst, J. J., Jeppesen, P. B., & Kissow, H. (2021) · Biomedicines · doi:10.3390/biomedicines9040383 · Cited by 65
“Furthermore, similar benefits were seen in obese adolescents [30].”
BackgroundMaffeis, C., Olivieri, F., Valerio, G., Verduci, E., Licenziati, M. R., Calcaterra, V., Pelizzo, G., Salerno, M., Staiano, A., Bernasconi, S., et al. (2023) · Italian Journal of Pediatrics · doi:10.1186/s13052-023-01458-z · Cited by 65
Hannon, T. S., & Arslanian, S. A. (2023) · New England Journal of Medicine · doi:10.1056/nejmcp2102062 · Cited by 61
Self-citationThe expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
“Liraglutide was studied in 251 participants aged 12–18 years with obesity who had suboptimal responses to previous lifestyle management interventions 110 .”
InfluentialSevere Obesity in Children and Adolescents: Metabolic Effects, Assessment, and Treatment
Chung, L. Y., & Rhie, Y. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21063 · Cited by 74
GLP-1 programs the neurovascular landscape
Chen, B., Yu, X., HORVATH-DIANO, C., Ortuño, M. J., Tschöp, M. H., Jastreboff, A. M., & Schneeberger, M. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.003 · Cited by 62
Effect of Pediatric Obesity Treatment on Long-Term Health
Putri, R. R., Danielsson, P., Ekström, N., Ericsson, Å., Lindberg, L., Marcus, C., & Hagman, E. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2024.5552 · Cited by 77
Self-citationGastric Sensory and Motor Functions and Energy Intake in Health and Obesity—Therapeutic Implications
Cifuentes, L., Camilleri, M., & Acosta, A. (2021) · Nutrients · doi:10.3390/nu13041158 · Cited by 57
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
Rolek, B., Haber, M., Gajewska, M., Rogula, S., Pietrasik, A., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080322 · Cited by 77
“The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial [19] was designed to evaluate the effects of canagliflozin on renal outcomes in patients with T2DM and albuminuric chronic kidney disease.”
BackgroundMazur, A., Zachurzok, A., Baran, J., Dereń, K., Łuszczki, E., Weres, A., Wyszyńska, J., Dylczyk, J., Szczudlik, E., Drożdż, D., et al. (2022) · Nutrients · doi:10.3390/nu14183806 · Cited by 77
Managing obesity in children: a clinical practice guideline
Ball, G. D. C., Merdad, R., Birken, C. S., Cohen, T. R., Goodman, B., Hadjiyannakis, S., Hamilton, J., Henderson, M., Lammey, J., Morrison, K. M., et al. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.241456 · Cited by 56
“It is likely that discontinuing medication will lead to weight regain and regression of improvements to health outcomes, 44,45 which highlights the importance of long-term multicomponent interventions for managing obesity as a chronic disease.”
Kelly, A. S., Arslanian, S. A., Hesse, D., Iversen, A. T., Körner, A., Schmidt, S., Sørrig, R., Weghuber, D., & Jastreboff, A. M. (2023) · Obesity · doi:10.1002/oby.23808 · Cited by 65
Self-citationPharmacotherapy for obesity: moving towards efficacy improvement
Coutinho, W. F., & Halpern, B. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01233-4 · Cited by 70
“A RCT including adolescents with obesity demonstrated a significantly greater reduction in BMI with lira-glutide compared with placebo; 43.3% vs. 18.7% had at least a 5% reduction in BMI, and 26.1% vs. 8.1% had at least a 10% reduction [81].”
BackgroundInfluentialInsulin Resistance in Pediatric Obesity: From Mechanisms to Treatment Strategies
Luo, Y., Luo, D., Li, M., & Tang, B. (2024) · Pediatric Diabetes · doi:10.1155/2024/2298306 · Cited by 92
“…that the sub-cutaneous administration of liraglutide in combination with metformin (with or without basal insulin) safely and effectively reduced Hemoglobin A1c (HbA1c) levels in patients aged 10 – 17 years with T2DM, albeit at an increased incidence of gastrointestinal adverse reactions [172].”
Kanbour, S., Ageeb, R. A., Malik, R. A., & Abu-Raddad, L. J. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00346-2 · Cited by 75
Current and future pharmacotherapies for obesity in children and adolescents
Kelly, A. S. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00858-9 · Cited by 54
Self-citationPathophysiology and treatment of prediabetes and type 2 diabetes in youth
Bacha, F., Hannon, T. S., Tosur, M., Pike, J. M., Butler, A., Tommerdahl, K. L., & Zeitler, P. S. (2024) · Diabetes Care · doi:10.2337/dci24-0029 · Cited by 57
How to Practice Academic Medicine and Publish from Developing Countries? A Practical Guide
Nundy, S., Kakar, A., & Bhutta, Z. A. (2021) · Springer eBooks · doi:10.1007/978-981-16-5248-6 · Cited by 72
Pediatric Obesity: Complications and Current Day Management
Vajravelu, M. E., Tas, E., & Arslanian, S. A. (2023) · Life · doi:10.3390/life13071591 · Cited by 74
Self-citationObesity: exploring its connection to brain function through genetic and genomic perspectives
Saeed, S., Bonnefond, A., & Froguel, P. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02737-9 · Cited by 60
14. Children and Adolescents: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s014 · Cited by 96
Pharmacotherapy of obesity: An update
Cignarella, A., Busetto, L., & Vettor, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105649 · Cited by 65
Cro, S., Kahan, B. C., Rehal, S., Chis Ster, A., Carpenter, J. R., White, I. R., & Cornelius, V. R. (2022) · BMJ · doi:10.1136/bmj-2022-070146 · Cited by 52
Fox, C. K., Clark, J. M., Rudser, K. D., Ryder, J. R., Gross, A. C., Nathan, B. M., Sunni, M., Dengel, D. R., Billington, C. J., Bensignor, M. O., et al. (2022) · Obesity · doi:10.1002/oby.23395 · Cited by 56
“However, it is worth noting that the largest randomized, placebo- controlled trial of a GLP1RA (liraglutide 3 mg) for adolescent obesity similarly showed only modest, non- statistically significant differences between the liraglutide and placebo arms in cardiometabolic variables and weight- related QOL after 56 weeks…”
BackgroundSelf-citationRisk Factors, Clinical Consequences, Prevention, and Treatment of Childhood Obesity
Shaban Mohamed, M. A., AbouKhatwa, M. M., Saifullah, A. A., Hareez Syahmi, M., Mosaad, M., Elrggal, M. E., Dehele, I. S., & Elnaem, M. H. (2022) · Children · doi:10.3390/children9121975 · Cited by 52
“In addition, it was reported that the most frequent associated adverse effects were the mild-to-moderate effects of gastrointestinal origin, mainly nausea, vomiting and diarrhea [87].”
BackgroundQuarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Quarenghi, R. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113791 · Cited by 65
Guidelines for treating child and adolescent obesity: A systematic review
Tully, L., Arthurs, N., Wyse, C. A., Browne, S., Case, L., McCrea, L., O’Connell, J., O’Gorman, C. S., Smith, S. M., Walsh, A., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.902865 · Cited by 66
Incretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
Hamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 94
“In a landmark development, liraglutide (Saxenda) was approved in 2020 for use in adolescents aged 12-17 years with a body weight above 60 kg and an initial BMI corresponding to ≥30 kg/m² for adults [17].”
MethodCaring for US Children: Barriers to Effective Treatment in Children with the Disease of Obesity
Srivastava, G., Browne, N. T., Kyle, T. K., O’Hara, V. M., Browne, A. F., Nelson, T., & Puhl, R. M. (2020) · Obesity · doi:10.1002/oby.22987 · Cited by 50
“Despite sufficient evidence to support behavioral therapy, MBS, and, most recently, pharmacotherapy (8), less than 1% of patients with severe childhood obesity receive treatment (5,9).”
BackgroundMonnier, L., Schlienger, J.-L., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.002 · Cited by 47
Managing early-onset type 2 diabetes in the individual and at the population level
Misra, S., Khunti, K., Goyal, A., Gable, D., Armocida, B., Tandon, N., Sachdev, P., Wild, S. H., Hivert, M.-F., & Beran, D. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01067-0 · Cited by 47
Ng, N. B. H., Low, Y. W., Rajgor, D. D., Low, J. M., Lim, Y. Y., Loke, K. Y., & Lee, Y. S. (2021) · Clinical Endocrinology · doi:10.1111/cen.14583 · Cited by 53
“In the past decade, GLP1‐RA has continued to improve its track record in managing obesity and T2DM, not only in adults but also the adolescent population.(31,32) These incretin mimetics are known to cause ghrelin suppression, central appetite suppression, increase energy expenditure and stimulate insulin secretion, wh…”
BackgroundSetmelanotide: A Novel Targeted Treatment for Monogenic Obesity
Pressley, H., Cornelio, C. K., & Adams, E. N. (2022) · Journal of Pharmacy Technology · doi:10.1177/87551225221116010 · Cited by 46
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2192865 · Cited by 56
“The approval of semaglutide and liraglutide for weight management has been met with considerable excitement [17,18].”
BackgroundInfluentialPharmacotherapy in pediatric obesity: current evidence and landscape
Singhal, V., Sella, A. C., & Malhotra, S. (2021) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000587 · Cited by 45
Metadata
- Authors
- Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S.
- Affiliations
- University of Minnesota (US)
- From the Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis (A.S.K.); Novo Nordisk, Søborg, Denmark (P.A.); Pediatric Endocrinology, Hospital Ángeles Puebla, Puebla City, Mexico (M.B.-P.); the Department of Pediatrics, Division of Pediatric Endocrinology, Universitair Ziekenhuis Brussel, Brussels (I.G.); Novo Nordisk, Plainsboro, NJ (P.M.H.); the Division of Pediatrics, Department of Clinical Science Intervention and Technology,...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-28
- Volume
- 382
- Issue
- 22
- Pages
- 2117-2128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013213902
- Cited by
- 723
- References
- 34
- Citations by year
- 2026: 133 · 2025: 143 · 2024: 149 · 2023: 109 · 2022: 80 · 2021: 80 · 2020: 26
- FWCI
- 44.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- liraglutide, adolescent obesity, childhood obesity, weight management, GLP-1 receptor agonists, lifestyle therapy, body mass index, gastrointestinal adverse effects, drug discontinuation, long-term weight maintenance, drug efficacy
- MeSH terms
- Liraglutide, Healthy Lifestyle, Adolescent, Blood Glucose, Child, Combined Modality Therapy, Double-Blind Method, Female, Gastrointestinal Diseases, Glycated Hemoglobin, Humans, Injections, Subcutaneous, Male, Body Mass Index, Incretins, Pediatric Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.